)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Micropos Medical
Micropos Medical (MPOS) investor relations material
Micropos Medical Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary30 Oct, 2026
Executive summary
Q3 activity was seasonally quieter in Europe, while commercial progress included new Spanish installations, a first MUSC patient, growing UK use and Swiss customer discussions.
Raypilot System had ~16 active customers, installations underway at ~4 more clinics and ~450 patients treated to date.
Financial highlights
Q3 2026 net sales were 679 TSEK vs 743 TSEK YoY; result after financial items was -5,594 TSEK vs -5,814 TSEK, with EPS of -SEK 0.03 in both periods.
Jan-Sep 2026 net sales were 2,272 TSEK vs 6,723 TSEK; result after financial items was -22,052 TSEK vs -15,604 TSEK, and EPS was -SEK 0.13 vs -SEK 0.09.
Jan-Sep operating loss widened to 22,164 TSEK from 15,331 TSEK; 538 TSEK of development work was capitalized, vs 0 TSEK a year earlier.
Jan-Sep cash flow was +1,490 TSEK vs +8,570 TSEK; period-end cash was 11,309 TSEK vs 16,560 TSEK.
Outlook and guidance
Priorities are to increase patient volumes at existing clinics, embed Raypilot System in routine care and develop recurring sales of consumables.
Product development will accelerate as regulatory work eases, with customer experience informing system functionality and clinical workflows.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Micropos Medical
- Sales fell and losses widened, but NHS adoption and new funding boost future prospects.MPOS
Q2 2026 - Sales and equity fell, but MDR certification and new deals highlight growing clinical traction.MPOSQ1 2026
- Net sales surged 113% year-over-year, but continued losses highlight the need for new capital.MPOSQ4 2025
- Net sales surged and losses narrowed, but new capital will be needed in early 2026.MPOSQ3 2025
- Net sales doubled and cash strengthened, with Raypilot System adoption accelerating in Europe.MPOSQ2 2025
- First US order and strong clinical evidence position Micropos for growth as SBRT adoption rises.MPOSQ3 2024
- Sales up, losses down, and Raypilot System gains traction in key European markets.MPOSQ2 2024
- Strong sales growth and full rights issue support expansion and clinical adoption.MPOSQ1 2025
- Strong sales growth and SBRT momentum drive Raypilot System adoption, but liquidity risks persist.MPOSQ4 2024
Next Micropos Medical earnings date
Q4 202629 Jan, 2027
Micropos Medical
Next Micropos Medical earnings date
Q4 202629 Jan, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Micropos Medical is a medical technology company specializing in the development of innovative solutions for precision radiotherapy in cancer treatment. The company focuses on improving the accuracy and efficiency of radiation therapy by offering advanced positioning and monitoring systems. Its technologies aim to enhance patient outcomes by enabling precise targeting of treatment areas while minimizing exposure to surrounding healthy tissues. The company is headquartered in Gothenburg, Sweden, and its shares are listed on the Nasdaq Stockholm.